Impact of ABCB1 variants on neutrophil depression: A pharmacogenomic study of paclitaxel in 92 women with ovarian cancer

Basic and Clinical Pharmacology and Toxicology

Volumn 110, Issue 2, 2012, Pages 199-204

  Bergmann, Troels K ^a,b   Brasch Andersen, Charlotte ^b,c   Gréen, Henrik ^d,e   Mirza, Mansoor R ^c   Skougaard, Kristin ^f   Wihl, Jessica ^g   Keldsen, Nina ^h   Damkier, Per ^c   Peterson, Curt ^d   Vach, Werner ⁱ   Brøsen, Kim ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d LINKÖPING UNIVERSITY   (Sweden)

^e ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^f GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h HERNING HOSPITAL   (Denmark)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYTOCHROME P450 2C8; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; ABCB1 PROTEIN, HUMAN; CYP2C8 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; CANCER PATIENT; DRUG METABOLISM; FEBRILE NEUTROPENIA; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEARING LOSS; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPHIL COUNT; OVARY CANCER; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSORY NEUROPATHY; TOXICITY TESTING; VOMITING; CAUCASIAN; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; GENOTYPING TECHNIQUE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEUTROPHIL; OVARIAN NEOPLASMS; PATHOLOGY; PHARMACOGENETICS; PROCEDURES; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; CYTOCHROME P-450 CYP2C8; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MIDDLE AGED; NEUTROPHILS; OVARIAN NEOPLASMS; P-GLYCOPROTEINS; PACLITAXEL; PATIENT COMPLIANCE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES;

EID: 84855964135     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00802.x     Document Type: Article

References (34)

1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996;23:40-7.
2. Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994;54:4026-35.
3. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994;54:5543-6.
4. Kumar G, Ray S, Walle T, Huang Y, Willingham M, Self S et al. Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6 alpha-hydroxytaxol. Cancer Chemother Pharmacol 1995;36:129-35.
5. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 1997;94:2031-5.
6. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11:597-607.
7. Soyama A, Saito Y, Hanioka N, Murayama N, Nakajima O, Katori N et al. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol Pharm Bull 2001;24:1427-30.
8. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137-43.
9. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-99.
10. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473-8.
11. Marsh S. Taxane pharmacogenetics. Personalized Med 2006;3: 33-43.
12. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 2005;116:824-9.
13. McFadyen MC, Cruickshank ME, Miller ID, McLeod HL, Melvin WT, Haites NE et al. Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer 2001;85:242-6.
14. McFadyen MCE, McLeod HL, Jackson FC, Melvin WT, Doehmer J, Murray GI. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol 2001;62:207-12.
15. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007;25: 4528-35.
16. Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007;81:76-82.
17. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, Kruh GD. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res 2004;64:4927-30.
18. Bergmann TK, Brasch-Andersen C, Green H, Mirza M, Pedersen RS, Nielsen F et al. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J 2011;11: 113-20.
19. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 2006;12:854-9.
20. Green H, Soderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EA et al. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 2009;104:130-7.
21. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. J Pharm Sci 2008;97:2045-8.
22. Nakajima M, Fujiki Y, Kyo S, Kanaya T, Nakamura M, Maida Y et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmacol 2005;45:674-82.
23. Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 2006;42:2893-6.
24. Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol 2009;113:264-9.
25. Bergmann TK, Green H, Brasch-Andersen C, Mirza MR, Herrstedt J, Holund B et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol 2011; 67:693-700.
26. Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006;79:570-80.
27. Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM et al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 2008; 14:4543-9.
28. Tsai SM, Lin CY, Wu SH, Hou LA, Ma H, Tsai LY et al. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms. Clin Chim Acta 2009;404:160-5.
29. Vach W, Bergmann TK, Brosen K. No evidence for taxane/platinum pharmacogenetic markers: just lack of power? J Clin Oncol 2008;26:1903-4.
30. Branford RA, Pantelidis P, Ross JR. Ethnic considerations in pharmacogenetic studies. J Clin Oncol 2008;26:1766-7.
31. Maitland ML, Ratain MJ, Cox NJ. Interpreting P values in pharmacogenetic studies: a call for process and perspective. J Clin Oncol 2007;25:4513-5.
32. Leskela S, Jara C, Leandro-Garcia LJ, Martinez A, Garcia-Donas J, Hernando S et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 2011;11:121-9.
33. Fjallskog ML, Frii L, Bergh J. Paclitaxel-induced cytotoxicity - the effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein. Eur J Cancer 1994;30A:687-90.
34. Huls M, Russel FG, Masereeuw R. The role of ATP binding cassette transporters in tissue defense and organ regeneration. J Pharmacol Exp Ther 2009;328:3-9.